PhytoHealth

What PhytoHealth does

PhytoHealth (懷特生技新藥, TWSE: 4108) is a Taiwan-based botanical pharmaceutical company founded in 1998 and recognized as Taiwan's first listed new drug R&D company. The company operates as part of the Mayo-PhytoHealth-Anke BioTech Group (美吾華·懷特·安克生技集團) and develops proprietary plant-derived drugs using a disease-targeted methodology built around purified Astragalus polysaccharide (PG2 / 精製黃耆多醣) extracts. Its flagship commercial product, PhytoHealth Blood Treasure (PG2 / 懷特血寶), is the world's only approved prescription drug for cancer-related fatigue (CRF) — an ICD-10 classified condition — and was Taiwan's first TFDA-approved botanical new drug, listed on National Health Insurance (NHI) reimbursement since March 2021 for advanced breast cancer patients.

The company operates across three product layers: (1) prescription pharmaceuticals — PG2 for cancer-related fatigue and Oraphine (懷特痛寶), a nalbuphine oral capsule for moderate-to-severe acute pain with low addiction and low respiratory depression profile; (2) a pipeline of US FDA Phase IIa-completed botanical drug candidates — PhytoHealth Bone Treasure (懷特骨寶) for bone disease and PhytoHealth Sugar Treasure (懷特糖寶) for diabetic kidney disease; and (3) a portfolio of health supplements (PhytoHealth Qi-Li, An-Su, Huang-Qi-Yin) leveraging the same Astragalus polysaccharide platform for post-cancer care and consumer wellness markets. The business model combines direct hospital sales with NHI reimbursement for volume-driven adoption in Taiwan and self-pay channels for expanded indications and international markets, supplemented by an emerging licensing and co-development pathway for international expansion. Leadership is headed by Chairman and CEO Lee Yi-Chi (李伊俐) with four independent directors including Audit Committee convener Lin Shui-Long (林水龍).

Name

PhytoHealth

Legal name

懷特生技新藥股份有限公司

Website

https://phytohealth.com.tw

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

PhytoHealth (TWSE: 4108) is a Taiwan-listed botanical drug company that develops plant-based pharmaceuticals using purified Astragalus polysaccharide technology, with lead product PG2 being the world's only approved prescription treatment for cancer-related fatigue and NHI-reimbursed in Taiwan.

Ownership category

akta.pro rank

Product category

Botanical Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

akta.pro secondary industries

Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD), Herbal & Botanical Supplements (CRADAGAD)

Keywords

• Botanical drug development
• Cancer-related fatigue treatment
• Plant-based pharmaceuticals
• Pain management medication
• Health supplement products

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Revenue from prescription pharmaceutical products including PhytoHealth Blood Treasure (PG2) for cancer-related fatigue and Oraphine for pain management, sold through hospital channels with NHI reimbursement in Taiwan and self-pay expansion internationally.
2. Health Supplement Products: Revenue from functional health food products developed using proprietary botanical technology, positioned as post-cancer care and wellness market expansion.
3. Licensing and Technology Transfer: Potential revenue from out-licensing products and co-development partnerships, including product/project licensing of PhytoHealth Blood Treasure, Pain Relief, Bone Protection, and Sugar Protection to international partners.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

PhytoHealth is a Taiwan-based pharmaceutical company that develops and commercializes disease-targeted botanical (plant-based) new drugs derived from purified Astragalus polysaccharide (PG2). Its two commercialized products are PhytoHealth Blood Treasure (PG2) lyophilized injection for cancer-related fatigue—the world's only approved prescription treatment for CRF and Taiwan's first TFDA-approved botanical new drug—and Oraphine (nalbuphine) soft capsule for post-surgical acute pain with low addiction profile. The company also sells health supplements and has pipeline candidates for bone disease and diabetic kidney disease.

Product overview

PhytoHealth (懷特生技新藥) is Taiwan's first listed botanical new drug R&D company. The company operates two commercialized core drugs (懷特血寶® for cancer-related fatigue and 懷特痛寶® for pain management) and a pipeline of investigational botanical drugs (懷特骨寶® and 懷特糖寶®) targeting bone health and diabetic kidney disease respectively. The product portfolio spans prescription pharmaceutical drugs, over-the-counter health supplements (懷特耆力®, 懷特胺速®, 懷特皇耆飲®), and a dedicated R&D center for purified Astragalus polysaccharide technology. The company leverages its disease-targeted plant drug development model, validated by TFDA's first botanical new drug approval for 懷特血寶®.

Differentiator

Problem solved

Functional benefit

Brands

• 懷特血寶: PG2, a plant-based new drug for Cancer-Related Fatigue (CRF). Taiwan's first TFDA-approved botanical new drug. Used for cancer-related fatigue in cancer patients.
• 懷特痛寶 (Oraphine)
• 懷特骨寶
• 懷特糖寶
• 懷特耆力
• 懷特胺速
• 懷特皇耆飲
• 精製黃耆多醣

Products and services

• PhytoHealth Blood Treasure (PG2) Lyophilized Injection (懷特血寶®凍晶注射劑) The world's first and only approved prescription drug for Cancer-Related Fatigue (CRF), extracted from Astragalus (黃耆). Taiwan TFDA's first botanical new drug approval, with 15 years of clinical evidence and listed as first-line standard treatment for moderate-to-severe cancer fatigue. Covered under Taiwan NHI reimbursement for advanced breast cancer patients. Real-world evidence shows 91% patient improvement rate.
• Oraphine Soft Capsule (懷特痛寶®軟膠囊)

Quantifiable outcome

• 91% patient improvement rate in cancer fatigue symptoms
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered flagship and core.

• Aristro Pharma (Germany)flagshipChannel Partner/ Reseller/ Distributor · 1 January 2025Partnership with German pharmaceutical company Aristro Pharma for regulatory registration and distribution of Oraphine (pain medication) in Germany. Letter of Intent signed in Q1 2025 with regulatory registration planned for Q4 2025, targeting the approximately USD 200 million German pain medication market.
• Indena S.p.A.coreStrategic or Co-development Partner · 27 February 2024Partnership with Italian phytochemical raw materials manufacturer Indena for joint development of botanical raw materials. Indena will assist with regulatory registration and EU market sales for botanical products. Indena is a century-old professional botanical extraction company and the primary raw material supplier for Paclitaxel, the most widely used cancer drug globally, with 4 production bases and business in 80+ countries.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Regional players

• TaiGen Biotechnology: Taiwan-listed biopharma developing novel therapeutics with both domestic commercialization and international out-licensing strategy. Comparable as an Asia-listed R&D pharma with hospital-channel distribution and pipeline-driven growth model.
• Yung Shin Pharmaceutical: Taiwan-based pharmaceutical company developing and commercializing specialty drugs including oncology supportive care. Comparable as a Taiwan public pharma with similar hospital-channel distribution and NHI reimbursement model.
• PharmaEngine: Taiwan-listed (TPEx) specialty pharma focused on oncology drug development and licensing. Comparable as a Taiwan-headquartered public pharma developing novel cancer therapeutics with international partnership-driven commercialization strategy.

Direct peers

• Kunming Pharmaceutical: China-based botanical pharmaceutical company developing plant-derived drugs for oncology and supportive care. Comparable as an Asia-rooted botanical pharma R&D company with traditional medicine-based commercialized products.
• Hutchison China MediTech (HUTCHMED): China-rooted pharmaceutical company that develops botanical-derived and targeted oncology therapies, including compounds for cancer-related indications. Highly comparable as an Asia-listed R&D pharma commercializing novel oncology and supportive care drugs globally.
• Yiling Pharmaceutical: China-based pharmaceutical company focused on traditional Chinese medicine-derived (botanical) prescription drugs. Directly comparable business model of commercializing clinically validated botanical pharmaceutical products, with similar Astragalus and herbal product portfolios.
• Tsumura & Co. Japan-listed pharmaceutical company specializing in Kampo (traditional herbal) prescription medicines with clinical evidence base. Comparable as an Asia-listed botanical prescription pharma with hospital prescription channel and reimbursement-based model.

Others

• Indena S.p.A. Italy-based century-old botanical extraction and ingredient manufacturer; PhytoHealth's EU partner. Comparable as a botanical/phytopharmaceutical specialist working in the same plant-derived active ingredient and finished product value chain.

Broad incumbents

• Helsinn Group: Swiss specialty pharma focused on cancer supportive care and gastrointestinal products. Comparable as a cancer-related supportive care pharmaceutical company with hospital-channel distribution in similar oncology quality-of-life therapeutic areas.
• AMAG Pharmaceuticals (now part of Covis Pharma): Specialty pharma historically focused on cancer-related fatigue, postpartum hemorrhage, and supportive care. Comparable as a player in cancer-related fatigue supportive care, which directly overlaps PhytoHealth's core PG2 indication.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Astragalus3.0
• LinkedInlinkedin.com/company/maywufa

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhytoHealth